Highlights
- •Unique case of MOG-EM and lung cancer in a patient with intracranial lesions.
- •MOG-IgG detected in serum and CSF; patient was successfully treated with steroids.
- •Implications for early detection of MOG-IgG to avoid treatment delays.
Abstract
Background
Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of
oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated
encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary
diagnosis standard. Some patients with lung cancer have been reported to be seropositive
for onconeural antibodies; however, lung cancer cases with MOG-EM have not been previously
reported.
Methods
We report the case of a patient with lung adenocarcinoma with multiple intracranial
lesions found during molecular targeted therapy.
Results
The patient tested positive for MOG antibody in her cerebrospinal fluid, and the therapeutic
effect of steroids was excellent.
Conclusion
This is the first reported case of MOG-EM coincident with lung cancer in a patient
with multiple intracranial lesions. When patients present with a history of malignant
tumors or suspected paraneoplastic neurological syndrome, clinicians should also be
alert to the presence of other autoimmune antibodies such as MOG-IgG to avoid treatment
delay.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies.Mult. Scler. Relat. Disord. 2017; 18: 90-92
Jarius, S., et al., [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].Nervenarzt, 2018.89 (12): p. 1388–1399.
- Recommended diagnostic criteria for paraneoplastic neurological syndromes.J. Neurol. Neurosurg. Psychiatr. 2004; 75: 1135-1140
Henry, K., Paraneoplastic syndromes: definitions, classification, pathophysiology and principles of treatment.semin diagn pathol, 2019.36 (4): p. 204–210.
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.Journal of clinical oncology.Official J. Am. Soc. Clin. Oncol. 2008; 26: 4708-4713
Article info
Publication history
Published online: March 21, 2020
Accepted:
March 20,
2020
Received in revised form:
March 17,
2020
Received:
August 28,
2019
Identification
Copyright
© 2020 Elsevier B.V. All rights reserved.
